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 Synopsis 19 
Objectives: The increasing prevalence of extended-spectrum β-lactamase (ESBL)-producing 20 
Escherichia coli has been associated with the emergence of the CTX-M-producing sequence type 21 
131 (ST131) pandemic clonal group, a member of the O25b serogroup and the B2 phylogenetic 22 
group. To assess the clonal spread of ESBL-producing E. coli in Japan, a regional surveillance 23 
program was conducted. 24 
Methods: A total of 581 ESBL-producing clinical specimen E. coli isolates were collected between 25 
2001 and 2010. Clonal groups, including ST131, D-ST405, D-ST393, and D-ST69, were determined 26 
using the PCR O-type, phylogenetic grouping by triplex PCR, allele-specific PCR, and multilocus 27 
sequence typing (MLST). A subset of clonal groups underwent PFGE. 28 
Results: Among clonal strains, 215 isolates (37%) were identified as belonging to the ST131 group, 29 
185 as B2-ST131-O25b (32%), 26 as B2-ST131-O16 (4%), three as B1-ST131-O25b, and one as 30 
B2-ST131-O-non-typeable. Forty-one isolates (7%) were identified as D-ST405 clonal group, seven 31 
(1%) as D-ST69, and two (0.3%) as D-ST393. B2-ST131-O16 clonal group was characterised by 32 
CTX-M-14 and a significantly lower ciprofloxacin-resistant rate than B2-ST131-O25b clonal group. 33 
The B2-ST131-O16 and B2-ST131-O25b clonal groups each made up a single PFGE cluster, with 34 
65% similarity. The rate of ESBL-producing E. coli increased over the years (0.2% in 2001 to 9.7% 35 
in 2010) and corresponded to increases in the numbers of B2-ST131-O25b, B2-ST131-O16, and 36 
D-ST405 clonal groups. 37 
Conclusions: B2-ST131-O25b, B2-ST131-O16, and D-ST405 clonal groups have contributed to the 38 
spread of ESBL-producing E. coli in Japan. 39 
40 
 Introduction 41 
In recent years, the prevalence of extended-spectrum β-lactamase (ESBL)-producing 42 
Escherichia coli has increased dramatically worldwide.
1
 Clonal group detection by multilocus 43 
sequence typing (MLST) has suggested the reason for this pandemic. The emergence of an 44 
international pandemic clonal group, CTX-M-type ESBL-producing E. coli with sequence type 131 45 
(ST131) belonging to the O25b serogroup and the B2 phylogenetic group, has contributed greatly to 46 
the pandemic.
2
 The success of the ST131 clonal group is explained by its acquisition of 47 
fluoroquinolone resistance and additional virulence factors.
2
 In addition to the ST131 clonal group, a 48 
CTX-M-15-producing ST405 clonal group belonging to phylogenetic group D has been detected 49 
worldwide.
3
 However, the prevalence and evolution of this clonal group has not been well 50 
investigated. Detailed studies on the ST131 clonal group among ESBL-producing E. coli in Japan are 51 
lacking. 52 
Other clonal groups disseminated worldwide include D-ST393-O15 and D-ST69.
4-6
 The 53 
D-ST393-O15 clonal group is characterised by K52:H1 serotypes and fluoroquinolone resistance.
7
 54 
CTX-M-14 producers have also been identified.
8
 The D-ST69 clonal group is known as “clonal 55 
group A” and is frequently found among trimethoprim-sulfamethoxazole-resistant uropathogenic E. 56 
coli.
9
 A study conducted in 2009 in Spain indicated that these two clonal groups and the ST131 57 




In this study, we analysed the genetic relatedness of ESBL-producing E. coli isolates in 60 
2010 in the Kyoto and Shiga regions of Japan using random amplified polymorphic DNA (RAPD) 61 
fingerprinting and found that the B2-ST131-O16 clonal group was closely related to the 62 
B2-ST131-O25b clonal group. Then, we investigate the contribution and characteristics of the clonal 63 
groups, including ST131, ST405, ST393, and ST69. We further investigated ST131 variants that 64 
were non-B2 or non-O25b isolates, which mostly consisted of B2-ST131-O16 isolates. 65 
  66 
 67 
Materials and methods 68 
Bacterial isolates. This study was conducted at seven acute care hospitals in the Kyoto and Shiga 69 
regions of Japan. Between April 2001 and December 2010, 12,607 non-duplicate E. coli isolates 70 
were obtained from inpatients and outpatients. Of those, 643 isolates that tested positive in an ESBL 71 
confirmation test were sent to a reference laboratory (Kyoto University) and were further 72 
investigated. The collection was conducted every year, and the period of collection was different 73 
depending on the year. Isolates were collected and saved anonymously, without accompanying 74 
demographic data. 75 
Identification and susceptibility testing. At each hospital, microbiological identification and 76 
susceptibility testing were performed using the Vitek2 system (bioMérieux, Marcy l’Etoile, France) 77 
or the MicroScan system (Siemens Healthcare diagnostics, Tokyo, Japan). Subsequently, the ESBL 78 
screening test was performed according to the CLSI microdilution methodology (cefotaxime, 79 
ceftriaxone, ceftazidime, cefpodoxime, and aztreonam), and the ESBL confirmation test was 80 
performed using the double-disk synergy test following the CLSI guidelines.
10
 In a reference 81 
laboratory, the antibiotic susceptibility was re-evaluated by microdilution using Dry Plate Eiken 82 
(Eiken, Tokyo, Japan) and included testing with ampicillin-sulbactam, piperacillin-tazobactam, 83 
ciprofloxacin, gentamicin, tobramycin, amikacin, imipenem, meropenem, minocycline, and 84 
trimethoprim-sulfamethoxazole. The results were interpreted using the 2012 CLSI breakpoints.
10
 85 
Intermediate susceptibility to each antibiotic was considered to be resistance. 86 
β-lactamase identification. The presence of ESBL or plasmid-mediated AmpC β-lactamase 87 
(pAmpC) genes was detected by PCR amplification and sequencing of the CTX-M, TEM, SHV, 88 
OXA-1 genes, and the 6 main groups of pAmpC-type genes as described previously.
11
 The isolates 89 
that were resistant to imipenem or meropenem (MIC > 1 mg/L) were analysed to determine the 90 
 presence of the carbapenemases GES, OXA-48-like, IMP, VIM, KPC, and NDM.
12, 13
 91 
Detection of clonal groups. ESBL-producing isolates were analysed to determine their phylogenetic 92 
groups (A, B1, B2, and D) using the triplex PCR technique of Clermont et al.
14
 In addition, they 93 
were analysed to determine their PCR O type using PCR amplification of rfb variants (O1, O2, O4, 94 
O6, O7, O12, O15, O16, O18, O25a, O75, O157, and O25b).
15, 16
 95 
For the detection of the B2-ST131-O25b clonal group, the B2-ST131-O25b pabB allele-specific 96 
PCR (Clermont-pabB PCR) was performed as described by Clermont et al.
17
 The Clermont-pabB 97 
PCR targets a different region of the pabB gene from that used in the Pasteur MLST scheme. Isolates 98 
that belonged to phylogenetic group B2 and were positive for the O25b rfb allele and the 99 
Clermont-pabB PCR were classified into the B2-ST131-O25b clonal group. Twelve selected 100 
B2-ST131-O25b isolates identified by these presumptive methods were confirmed by MLST. 101 
Isolates that were positive for Clermont-pabB PCR but non-B2 or non-O25b were also subjected to 102 
MLST. 103 
For the detection of the B2-ST131-O16 clonal group, all of the phylogenetic B2 and O16 rfb-positive 104 
isolates were subjected to MLST. Isolates displaying a single-locus variant (SLV) of ST131 were 105 
also included in the ST131 clonal group. 106 
For the detection of the ST405 clonal group, adk35 allele-specific PCR and sequencing of the mdh 107 
allele were performed. Isolates that belonged to phylogenetic group D and were positive for the 108 
adk35 allele and mdh4 allele were classified as D-ST405 clonal group. Eight selected D-ST405 109 
isolates were confirmed by MLST. The primers adk35f (5’-TGGCAAACTGGTCACT-3’) and 110 
adk35r (5’-CGTTGACCGTATCGTC-3’) were designed for the detection of ST405-associated 111 
single-nucleotide polymorphisms in adk35 (i.e., C148T, T316C, T322C, and A331C). Amplification 112 
was performed with 1X PCR buffer, 2 mM MgCl2, 0.2 mM deoxynucleoside triphosphates, 0.4 μM 113 
of each primer, 1 U AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA), and 1 μL 114 
boiled cell lysate in a total volume of 20 μL. The cycling protocol was as follows: 95°C for 5 min, 115 
 then 30 cycles of 95°C for 20 s, 60°C for 20 s, 72°C for 20 s, and then a final extension at 72°C for 5 116 
min. 117 
For the detection of the D-ST393-O15 clonal group, isolates that were positive for the O15 rfb allele 118 
were sequenced to determine the fumC allele profile. All phylogenetic group D and 119 
fumC106-positive isolates were confirmed as ST393 clonal group by MLST. 120 
For the detection of the D-ST69 clonal group, fumC35 allele-specific PCR was performed as 121 
described previously.
18
 Phylogenetic group D and fumC35 PCR-positive isolates were sequenced to 122 
determine the fumC and gyrB allele profiles. The fumC35 and gyrB27 isolates were considered to 123 
comprise the D-ST69 clonal group. One randomly selected D-ST69 isolate was confirmed by MLST. 124 
MLST. MLST was performed according to the Achtman scheme (http://mlst.ucc.ie/mlst/dbs/Ecoli) 125 
using seven housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, and recA).
19
 The ST131 isolates 126 
determined by the Achtman scheme were further characterised by the Pasteur MLST scheme 127 
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/EColi.html) using eight housekeeping genes 128 
(dinB, icdA, pabB, polB, putP, trpA, trpB, and uidA). 129 
PCR genomic fingerprinting and PFGE. RAPD fingerprinting using a DAF4 primer
20
 was 130 
performed for the ESBL-producing isolates obtained in 2010 to analyse the genetic relatedness of the 131 
B2-ST131-O25b clonal group. Genomic DNA from all of the isolates subjected to the Achtman 132 
MLST underwent XbaI PFGE.
21
 The profiles obtained from RAPD or PFGE were analysed with 133 
GelCompar II, version 4.6 (Applied Maths, Sint-Martens-Latem, Belgium). Cluster analysis was 134 
applied using the unweighted pair-group method based on Dice coefficients to quantify the 135 
similarities. 136 
Phylogenetic grouping of B1-ST131-O25b isolates. 137 
To confirm the B1 phylogenetic grouping of the B1-ST131-O25b isolates, these isolates were tested 138 
for the chuA gene amplification using primer pairs only for chuA in triplicate because a failure to 139 
detect the chuA gene would classify an isolate into B1 phylogenetic group.
14
 In addition, other 140 
 primer pairs
22
 for the chuA gene were used. A phylogenetic tree was built using neighbour-joining 141 
method in the CLUSTAL X program for the ST131 isolates found in this study and the reference 142 
strains for the B1 and B2 phylogenetic groups from the ECOR collection.
23
 This analysis was based 143 
on the nucleotide sequence data for the seven genes used in the Achtman scheme and the eight genes 144 
used in Pasteur scheme, which were obtained from each MLST website. 145 
Plasmid-mediated quinolone resistance determinants. All of the ESBL-producing isolates were 146 
characterised based on their plasmid-mediated quinolone resistance (PMQR) determinants (qnrA, 147 
qnrB, qnrC, qnrS, and aac(6’)-Ib-cr).24 148 
Statistical analysis. All categorical variables were compared using Fisher’s exact test. A P value 149 
<0.05 was considered statistically significant. We conducted our statistical analysis using Stata, 150 




Recognition of the B2-ST131-O16 clonal group. The PCR analysis detected 185 ESBL-producing 155 
E. coli isolates in 2010. PCR O-typing identified 77 O25b isolates, 15 O1 isolates, and nine O16 156 
isolates that represented three major PCR O-types. The Clermont-pabB PCR-positive isolates 157 
included 75 B2-ST131-O25b isolates, two B1-ST131-O25b isolates, and one B2-ST131-ONT 158 
(O-non-typeable) isolate. RAPD analysis indicated two large clusters (comprised of 86 and 76 159 
isolates) and 10 small clusters that included less than 7 isolates with 50% similarity (data not shown). 160 
The largest cluster of 86 isolates was made up of 74 B2-ST131-O25b isolates, two B1-ST131-O25b 161 
isolates, one B2-ST131-ONT isolate, seven B2-O16 isolates, one B2-O6 isolate, and one B2-ONT 162 
isolate. These results prompted us to perform MLST analysis of the B2-O16 isolates. All of the nine 163 
B2-O16 isolates, including seven isolates in the largest cluster and two isolates in the second largest 164 
cluster, belonged to the ST131 group but were negative by the Clermont-pabB PCR. 165 
 Annual rate of ESBL-producing E. coli. Annual rate of ESBL-producing E. coli. Between 2001 166 
and 2010, a total of 581 ESBL-producing E. coli of the 643 isolates that were positive in the ESBL 167 
confirmation test were confirmed by PCR analysis and further characterised. Five hundred fifty-one 168 
isolates (94.8%) were positive for CTX-M, 28 isolates were positive for TEM- or SHV-type ESBL, 169 
and the other two isolates were positive for both CTX-M and TEM or SHV. Five isolates that were 170 
resistant to imipenem or meropenem did not harbour a carbapenemase. Ten CTX-M-producing 171 
isolates were co-producers of pAmpC (CMY-2, n=9; DHA-1, n=1). The rate of ESBL-producing E. 172 
coli has increased from 0.2% in 2001 to 9.7% in 2010 (Figure 1). 173 
Characteristics of the clonal groups. PCR O-typing of 581 ESBL-producing E. coli indicated 190 174 
O25b isolates and 26 O16 isolates. Two O25b isolates belonged to phylogenetic group D and were 175 
negative by the Clermont-pabB PCR. All of the B2-O16 isolates except one and all of the isolates 176 
that were positive by the Clermont-pabB PCR but non-B2 (n=3) or non-O25b (n=1) were classified 177 
as ST131 by MLST analysis. The other B2-O16 isolate belonged to a novel ST, ST2784, a SLV of 178 
ST131. ST2784 had a single nucleotide polymorphism in the fumC gene when compared with ST131. 179 
Therefore, 215 isolates (37%) belonged to the ST131 group, which included 185 B2-ST131-O25b 180 
isolates, 26 B2-ST131-O16 isolates, three B1-ST131-O25b isolates, and one B2-ST131-ONT isolate. 181 
Forty-one isolates (7%) were identified as D-ST405 clonal group, seven isolates (1%) as D-ST69, 182 
and two isolates (0.3%) as D-ST393. Figure 1 presents the increasing trends in the rates of the 183 
B2-ST131-O25b, B2-ST131-O16, and D-ST405 clonal groups, although some annual variation 184 
exists. 185 
Table 1 lists the antimicrobial susceptibilities and resistance genes of the clonal groups, including 186 
others group, which comprised all of the isolates not belonging to any clonal groups. The 187 
ciprofloxacin resistance rate of the B2-ST131-O25b clonal group (91%) was higher than others 188 
group (47%) and B2-ST131-O16 clonal group (19%). The minocycline resistance rate of the 189 
B2-ST131-O25b clonal group (12%) was lower than the B2-ST131-O16 clonal group (58%). The 190 
 B2-ST131-O25b clonal group (6%) was less frequently resistant to piperacillin-tazobactam than the 191 
D-ST405 clonal group (17%). CTX-M-14 (44%), CTX-M-27 (24%), and CTX-M-15 (18%) were the 192 
most frequent ESBLs noted in the B2-ST131-O25b clonal group. However, the B2-ST131-O16 and 193 
D-ST405 clonal groups more frequently produced CTX-M-14 and did not produce CTX-M-27. 194 
CTX-M-2 and SHV were less frequently found in B2-ST131-O25b than in others group. All of the 195 
41 D-ST405 isolates were resistant to ciprofloxacin. In addition, they were more frequently resistant 196 
to ampicillin-sulbactam and tobramycin than the B2-ST131-O25b or others group. All of the 197 
D-ST405 isolates, except one, produced CTX-M-14 or CTX-M-15. CTX-M-2 was not produced by 198 
any of the isolates. All of the seven D-ST69 isolates were susceptible to ciprofloxacin. The resistance 199 
rate to trimethoprim-sulfamethoxazole (57%) was similar to other isolates. CTX-M-2 was the most 200 
prevalent ESBL type (57%). Both D-ST393 isolates were resistant to ciprofloxacin and tested 201 
positive for CTX-M-15- or SHV-type ESBL. 202 
Pasteur MLST analysis of ST131 clonal group. All of the ST131 isolates identified by the 203 
Achtman MLST scheme were subjected to a Pasteur MLST analysis (Table 2). Nine of 12 204 
B2-ST131-O25b isolates, three B1-ST131-O25b isolates, and one B2-ST131-ONT isolate belonged 205 
to PST43, where PST indicates the ST under the Pasteur scheme. The other two B2-ST131-O25b 206 
isolates belonged to a novel PST, PST568, a SLV of PST43, and the other B2-ST131-O25b isolate 207 
belonged to PST527, a double-locus variant of PST43. Twenty-one of 26 B2-ST131-O16 isolates 208 
belonged to PST506. The other five B2-ST131-O16 isolates belonged to novel PSTs, PST566 or 209 
PST567, both of which were SLVs of PST506. 210 
PFGE analysis. 211 
All of the B2-ST131-O25b, B1-ST131-O25b, and B2-ST131-ONT isolates made up a cluster with 212 
67% similarity (Figure 2). All of the B2-ST131-O16 isolates made up a cluster with 67% similarity. 213 
All of these ST131 isolates made up a cluster with 65% similarity. D-ST405 and D-ST69 isolates had 214 
less than 55% similarity to ST131 isolates. 215 
 Phylogenetic grouping of B1-ST131-O25b isolates. 216 
The absence of the chuA gene in all of the three B1-ST131-O25b isolates was confirmed by retesting 217 
and performing PCR using different primers. The phylogenetic tree for the B1 and B2 reference 218 
strains and the nine ST131 variants, with regard to ST and PST (Table 2), showed that 219 




This study investigated the clonal groups present among ESBL-producing E. coli isolates collected 224 
by regional surveillance in Japan from 2001 to 2010, the era of the CTX-M-producing ST131 225 
pandemic clonal group. The rate of ESBL-producing E. coli increased along with the rates of the 226 
ST131 and ST405 clonal groups. We found that both the B2-ST131-O25b and B2-ST131-O16 clonal 227 
groups contributed to this situation. 228 
The B2-ST131-O25b is well recognised as an international pandemic clonal group.
1
 However, 229 
B2-ST131-O16 has not been previously described as either a pandemic or a major clonal group. We 230 
have found that 4% of ESBL-producing E. coli were in the B2-ST131-O16 clonal group, and are 231 
characterised by fluoroquinolone susceptibility and minocycline resistance. The B2-ST131-O16 232 
clonal group differs from B2-ST131-O25b clonal group by more than two loci in the Pasteur MLST 233 
scheme and also differs when compared by PFGE analysis. The Clermont-pabB PCR for the 234 
B2-ST131-O25b clonal group correctly identified the B2-ST131-O25b clonal group. However, the 235 
B2-ST131-O25b clonal group carried the pabB15 or pabB74 alleles, and the B2-ST131-O16 clonal 236 
group also carried the pabB74 allele. The allele could be carried by B2-ST131-O25b and 237 
B2-ST131-O16 because the targeted pabB gene segment differs in the Clermont-pabB PCR and 238 
Pasteur MLST scheme. A recent Australian study described 211 B2-ST131-O25b and two 239 
B2-ST131-O16 isolates along with one B2-ST131-O157 isolate that were identified among 240 
 fluoroquinolone-resistant extraintestinal E. coli infections from humans and companion animals.
25
 241 
Peirano et al. investigated bloodstream ESBL-producing E. coli in Canada and found 113 ST131 242 
isolates that tested positive when subjected to Clermont-pabB PCR and had > 60% similarity in their 243 
PFGE profiles.
26
 The researchers also found 4 ST131 isolates that tested negative when subjected to 244 
Clermont-pabB PCR and had < 60% similarity in their PFGE profiles with those 113 ST131 isolates. 245 
These 4 isolates were possibly B2-ST131-O16 isolates. These two studies suggest the 246 
B2-ST131-O16 may be a candidate for an international clonal group. 247 
B2-ST131-O25b variants other than B2-ST131-O16 were also identified: B1-ST131-O25b and 248 
B2-ST131-ONT. The same PST was observed among all B1-ST131-O25b and some 249 
B2-ST131-O25b isolates, and these isolates had > 85% similarity in the PFGE analysis. According to 250 
the population structure of E. coli, it is impossible that ST131 belongs to the B1 and B2 phylogenetic 251 
branches of the E. coli population. We confirmed that three B1-ST131-O25b isolates found in this 252 
study were classified into the B1 phylogenetic group by the widely used triplex PCR method.
14
 253 
However, this method is known to be less reliable than the MLST-based method.
27
 The phylogenetic 254 
tree in Figure 3 shows that the B1-ST131-O25b isolates should be classified into the B2 phylogenetic 255 
group. B2-ST131-ONT was also close to B2-ST131-O25b by the Pasteur MLST scheme and PFGE 256 
analysis. In addition, both B1-ST131-O25b and B2-ST131-ONT can be detected using 257 
Clermont-pabB PCR. When investigating the ST131 clonal group, these ST131 variants should be 258 
taken into consideration. In addition to the testing for O25b rfb, testing for O16 rfb is recommended. 259 
Allele-specific PCR targeting gyrB and mdh of ST131
7
 may be an alternative method to correctly 260 
identify the ST131 clonal group. 261 
CTX-M-15 is most closely associated with the ST131 clonal group and thus is the most widely 262 
distributed CTX-M subtype. CTX-M-14 was the most prevalent among our B2-ST131-O25b isolates, 263 
followed by CTX-M-27 and CTX-M-15. In a Japanese nationwide surveillance study conducted 264 
between 2002 and 2003, most of the ST131 clonal group harboured CTX-M-14
28
, which was 265 
 consistent with our results. However, none of the isolates belonging to the previous ST131 clonal 266 
group harboured CTX-M-27 or CTX-M-15. Therefore, CTX-M-27 and CTX-M-15 emerged as new 267 
ESBL types. In other studies, CTX-M-14-producing ST131 was the most prevalent isolate in Spain
29
 268 




. The ST131 clonal group frequently harbours 269 
genes for TEM-1, OXA-1, and aac(6’)-Ib-cr.2 In our study, these associations were not observed. 270 
D-ST405 was the second-most prevalent clonal group (7%) in our study. All of the D-ST405 isolates 271 
were resistant to ciprofloxacin and predominantly harboured CTX-M-14 and CTX-M-15. In Korea 272 
(21%)
30
 and Canada (7%)
26
, D-ST405 was also the second-most prevalent ESBL-producing clonal 273 
group. Both studies reported CTX-M-15 and CTX-M-14 was the most prevalent ESBL. As far as we 274 
know, the only study which investigated the epidemiology and ciprofloxacin susceptibility of the 275 
ESBL-producing D-ST405 clonal group is a Canadian one.
26
 This study reported that all 14 D-ST405 276 
isolates were resistant to ciprofloxacin. These results suggest that the ciprofloxacin-resistant, 277 
CTX-M-14- and CTX-M-15-producing D-ST405 isolates compose another pandemic clonal group. 278 
D-ST69 has never been reported as an ESBL producer.
6
 We have identified seven ESBL-producing 279 
D-ST69 isolates but the rate was only 1%. Only two D-ST393 isolates were identified. These clonal 280 
groups were of little importance in terms of prevalence among the ESBL producers in our study. 281 
In conclusion, the increasing rate of ESBL-producing E. coli in the Kyoto and Shiga regions of Japan 282 
is associated with increases in the rates of the B2-ST131-O25b, B2-ST131-O16, and D-ST405 clonal 283 
groups. The importance of these clonal groups, especially ST131 and ST405, appears to be 284 
underscored by the fact that collectively B2-ST131-O25b, B2-ST131-O16, and D-ST405 clonal 285 
groups comprised 43% of the ESBL-producing E. coli in our study. The rates of the already 286 
world-wide pandemic clonal groups, B2-ST131-O25b and D-ST405, are not striking. However, the 287 
B2-ST131-O16 clonal group may be worth special attention. This clonal group should be 288 
investigated to clarify its spread in other geographical areas, clinical significance, and 289 
microbiological characteristics, as it might have been overlooked in previous studies. 290 
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Table 1. Characteristics of B2-ST131-O25b, B2-ST131-O16, D-ST405, D-ST69, and D-ST393 clonal groups in ESBL-producing E. coli. 397 









 D-ST405 D-ST69 D-ST393 ‘others’ 
 
 B2-ST131-O25b vs. 
ST40
5 vs. 









Antimicrobial resistance              
 Ampicillin-sulbactam 131 (71%) 23 (88%) 4 (100%) 39 (95%) 7 (100%) 1 (50%) 245 
(78%) 
 0.003 0.062 0.001 0.109 0.007 
 Piperacillin-tazobactam 11 (6%) 3 (12%) 2 (50%) 7 (17%) 0 (0%) 0 (0%) 31 (10%)  0.048 0.389 0.026 0.181 0.176 
 Imipenem 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (1%)  1.000 1.000 1.000 1.000 1.000 
 Meropenem 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 4 (1%)  0.615 0.127 1.000 1.000 1.000 
 Ciprofloxacin 168 (91%) 5 (19%) 4 (100%) 41 (100%) 0 (0%) 2 (100%) 148 
(47%) 
 <0.001 <0.001 0.047 <0.001 <0.00
1 
 Gentamicin 50 (27%) 3 (12%) 2 (50%) 17 (41%) 2 (29%) 0 (0%) 76 (24%)  0.085 0.097 0.088 0.458 0.023 
 Tobramycin 46 (25%) 3 (12%) 0 (0%) 21 (51%) 2 (29%) 0 (0%) 57 (18%)  <0.001 0.213 0.001 0.085 <0.00
1 
 Amikacin 1 (1%) 0 (0%) 0 (0%) 2 (5%) 0 (0%) 0 (0%) 4 (1%)  0.318 1.000 0.086 0.656 0.143 
 Minocycline 22 (12%) 15 (58%) 1 (25%) 9 (22%) 2 (29%) 2 (100%) 115 
(36%) 
 <0.001 <0.001 0.128 <0.001 0.081 
Trimethoprim- 95 (51%) 13 (50%) 1 (25%) 28 (68%) 4 (57%) 2 (100%) 186 
(59%) 









19 (73%) 2 (50%) 30
b




 0.001 0.006 0.001 0.458 0.002 
 CTX-M-15 33
b
 (18%) 2 (8%) 0 (0%) 12
b




 0.089 0.265 0.128 0.308 0.022 
 CTX-M-2 17 (9%) 1 (4%) 2 (50%) 0 (0%) 4 (57%) 0 (0%) 58 (18%)  <0.001 0.705 0.047 0.006 0.043 





 (2%) 0 (0%) 0 (0%) 0 (0%) 1 (14%) 0 (0%) 11 (3%)  0.367 0.496 1.000 0.588 0.623 
 CTX-M-24 4 (2%) 0 (0%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 4 (1%)  0.715 0.496 1.000 0.475 0.459 
 CTX-M-9 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 9 (3%)  0.204 0.127 1.000 0.030 0.606 
 Other CTX-M
d
 0 (0%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 17 (5%)  0.013 0.123 1.000 <0.001 0.237 
 TEM-type ESBL 2 (1%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (1%)  0.498 0.327 1.000 1.000 1.000 
SHV-type ESBL 3 (2%) 2 (8%) 0 (0%) 0 (0%) 0 (0%) 1 (50%) 18 (6%)  0.027 0.116 1.000 0.036 0.244 
Other β-lactamase              
 CMY-2 2 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 7 (2%)  0.813 0.335 1.000 0.496 1.000 
 DHA-1 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0%)  1.000 0.127 1.000 1.000 1.000 
 TEM-1 85 (46%) 10 (38%) 4 (100%) 16 (39%) 3 (43%) 1 (50%) 127 
(40%) 
 0.266 0.532 0.489 0.224 1.000 
 OXA-1 7 (4%) 0 (0%) 0 (0%) 3 (7%) 0 (0%) 0 (0%) 7 (2%)  0.425 1.000 0.394 0.400 0.095 
21 
 
PMQR determinants              
qnr 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 5
e
 (2%)  0.465 0.127 1.000 0.163 1.000 
 aac(6’)-Ib-cr 16 (9%) 0 (0%) 0 (0%) 4 (10%) 0 (0%) 0 (0%) 16 (5%)  0.419 0.703 0.766 0.131 0.267 
a
 Three B1-ST131-O25b isolates and one B2-ST131-ONT isolate were included. 398 
b
 One B2-ST131-O25b isolate, two D-ST405 isolates, and three isolates in the Others group were positive for both CTX-M-14 and CTX-M-15. 399 
c 
Two isolates were positive for both CTX-M-14 and CTX-M-3. 400 
d 
CTX-M-55 was found in the B2-ST131-O16 group and CTX-M-55 (n=6), CTX-M-1 (n=5), CTX-M-65 (n=2), CTX-M-19 (n=1), CTX-M-30 (n=1), 401 
CTX-M-44 (n=1), and CTX-M-126 (n=1) were identified in the Others group. 402 
e














ST dinB icdA pabB polB putP trpA trpB uidA 
9 B2 25b 131 43 9 1 15 7 4 9 6 9 
2 B2 25b 131 568 9 1 74 7 4 9 6 9 
1 B2 25b 131 527 9 20 15 7 4 9 6 129 
3 B1 25b 131 43 9 1 15 7 4 9 6 9 
1 B2 Non- typeable 131 43 9 1 15 7 4 9 6 9 
20 B2 16 131 506 9 134 74 134 4 72 1 9 
4 B2 16 131 567 9 20 74 134 4 72 1 9 
1 B2 16 2784 506 9 134 74 134 4 72 1 9 
1 B2 16 131 566 9 1 74 134 4 72 1 9 
Of 185 putative ESBL-producing B2-ST131-O25b isolates, 12 randomly selected isolates were subjected to MLST analysis. All of the 26 B2-O16, 3 407 




Figure legends 410 
 411 
Figure 1. Rates of the B2-ST131-O25b, B2-ST131-O16, and D-ST405 clonal groups among ESBL-producing 412 





Figure 2. PFGE of XbaI-digested DNA from the ST131, D-ST405, and D-ST69 clonal groups. In addition to 416 
all of the B2-ST131-O16, B1-ST131-O25b, and B2-ST131-O-non-typeable isolates, 12 B2-ST131-25b, eight 417 
D-ST405, and one D-ST69 isolate identified using the Achtman MLST scheme were included. Two D-ST393 418 
isolates were non-typeable. ST indicate the STs under the Achtman scheme, whereas PST indicates the STs 419 









Figure 3. Phylogenetic tree of the ECOR reference strains of B1 and B2 phylogenetic groups and the nine 425 
variants of ST131 clonal group detailed in Table 2. This tree was constructed from the concatenated nucleotide 426 
sequence of the seven genes used in the Achtman scheme and the eight genes used in the Pasteur scheme with 427 
the neighbour-joining method. 428 
 429 
